SELLAS LIFE SCIENCES GROUP I

SLSNASDAQ

🏆 #1878 by market capEarnings Nov 11US Equity

$11.51▼ $0.08 (−0.69%)

After hours · at close

🔔

Track SLS

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 0.7%

7d▼ 4.3%

14d▲ 1.9%

30d▼ 12.6%

ytd▲ 204.1%

1y▲ 642.6%

🏦Market Cap

$2.26B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

93.1%

High

💵FCF Margin

—

⚖️P/S Ratio

808.5x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $11.44 – $11.72
52-Week Range: $1.39 – $15.88
Volume: $5.68B
Avg Volume: $6.25B
Shares Outstanding: 196.6M
Next Earnings: Oct 19, 2026

Fundamentals Snapshot

Annual Revenue: $3M
Last Q Revenue: $668,383
P/E Ratio: —
P/S Ratio: 808.5x
EPS (TTM): $-0.22
Dividend Yield: —
Dilution (1yr): +106.9%

Why Investors Own SLS

✓High-growth profile — revenue up +21.1% YoY with expanding US Equity exposure.
✓Healthy economics — 39% gross margin and 5% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SELLAS LIFE SCIENCES GROUP I

SLS

Financial Trends

Revenue

$0▲ +0.0% YoY

Gross Margin

90.0%▼ −7.6% YoY

Operating Income

−$28M▼ −10.3% YoY

Free Cash Flow

−$28M▼ −19.8% YoY

Shares Outstanding

153.1M▲ +106.9% YoY

Net Cash

$71M▲ +$58M YoY

StockOtter · stockotter.space

About SELLAS LIFE SCIENCES GROUP I

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

🦦